Esketamine is a novel antidepressant approved by the US Food and Drug Administration (FDA) in 2019, but comprehensive studies on the post-marketing safety evaluation of esketamine across age groups remain limited. The objective of this study is to provide the age-based pharmacovigilance profile of esketamine and the potential toxicological mechanisms, which may provide insights to inform the...
This study assessed the clinical impact of mindfulness meditation training combined with probiotics on children with hypospadias. A total of 126 children with hypospadias undergoing treatment in Capital Center For Children's Health, Capital Medical University from December 2021 to December 2023 were recruited as the study participants. They were randomly divided into a control group (CG) and a...